UPDATE 1-Regeneron profit edges past estimates
February 09, 2017 at 07:00 AM EST
Feb 9 (Reuters) - Regeneron Pharmaceuticals Inc's adjusted profit edged past analysts' estimates helped by its flagship eye drug Eylea, even as lower-than-expected demand for its cholestrol-fighter Praluent hit revenue.